Association between anti-β2 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: a prospective study of 155 cases

被引:36
|
作者
Shen, Y. [1 ]
Chen, X-W [1 ]
Sun, C-Y [1 ]
Dai, M. [1 ]
Yan, Y-C [2 ]
Yang, C-D [1 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Rheumatol, Shanghai 200001, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Nephrol, Shanghai 200001, Peoples R China
基金
中国国家自然科学基金;
关键词
anti-beta 2 glycoprotein I antibodies; C4d; glomerular microthrombosis; lupus nephritis; ANTIPHOSPHOLIPID SYNDROME; THROMBOTIC MICROANGIOPATHY; COMPLEMENT ACTIVATION; ERYTHEMATOSUS; CLASSIFICATION; GLOMERULONEPHRITIS; ANTICARDIOLIPIN; PREVALENCE; CRITERIA; CELLS;
D O I
10.1177/0961203310368409
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glomerular microthrombosis (GMT) is a common vascular change in patients with lupus nephritis (LN). The mechanism underlying GMT is still unknown. In our previous study, we found that the level of IgG anti-beta 2 glycoprotein I (beta 2GPI) antibodies was higher in the LN-GMT group than in the LN-non-GMT group, which indicated that anti-beta 2GPI antibodies may play a role in GMT formation. Many studies have demonstrated that the activation of the classical complement pathway may play a critical role in fetal loss and aPL-induced thrombosis formation. To investigate whether complement activation plays a role in GMT formation and to evaluate its relationship with aPL, we prospectively investigated deposition of C4d in 155 renal biopsy specimens of LN patients. The results revealed a strong relationship between the intensity of glomerular C4d staining and the presence of microthrombi (p < 0.001). The detection rate of IgG anti-beta 2GPI antibodies was higher in the LN-GMT group than in the LN-non-GMT group (p < 0.05). Further, the intensity of glomerular C4d staining was significantly related with IgG anti-beta 2GPI antibodies (p < 0.05). The results of our study suggest that anti-beta 2GPI antibodies may play a role in GMT formation, and this process might involve complement activation. Lupus (2010) 19, 1195-1203.
引用
收藏
页码:1195 / 1203
页数:9
相关论文
共 25 条
  • [21] Study of β2-Glycoprotein I Polymorphisms in Patients With Chronic Renal Failure as a Predisposing Factor for the Development of Anti-β2-Glycoprotein I Auto-Antibodies
    Serrano, M.
    Cabrera-Marante, O.
    Martinez-Flores, J. A.
    Morales, P.
    Perez, D.
    Mora, S.
    Garcia, F.
    Gonzalez, E.
    Paz-Artal, E.
    Morales, J. M.
    Serrano, A.
    TRANSPLANTATION PROCEEDINGS, 2016, 48 (09) : 2876 - 2879
  • [22] Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study
    Jessica J Manson
    Alexander Ma
    Pauline Rogers
    Lesley J Mason
    Jo H Berden
    Johan van der Vlag
    David P D'Cruz
    David A Isenberg
    Anisur Rahman
    Arthritis Research & Therapy, 11
  • [23] Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study
    Manson, Jessica J.
    Ma, Alexander
    Rogers, Pauline
    Mason, Lesley J.
    Berden, Jo H.
    van der Vlag, Johan
    D'Cruz, David P.
    Isenberg, David A.
    Rahman, Anisur
    ARTHRITIS RESEARCH & THERAPY, 2009, 11 (05)
  • [24] The concomitant presence of lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies could be associated with acquired activated protein C resistance in non-systemic lupus erythematosus patients
    Gennari, L
    Blanco, A
    Alberto, MF
    Grosso, S
    Lazzari, MA
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (03) : 527 - 529
  • [25] Association between the prevalence of antibodies to β2-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications
    Nojima, J
    Kuratsune, H
    Suehisa, E
    Futsukaichi, Y
    Yamanishi, H
    Machii, T
    Iwatani, Y
    Kanakura, Y
    CLINICAL CHEMISTRY, 2001, 47 (06) : 1008 - 1015